conversation
Using Social Media in a Crisis : Distribute a Product Safety Widget Is One Idea
The “Social Media During a Crisis” roundtable discussion lead by Deborah Sittig ( @GreenRoomMedia ), Partner at Green Room Public Relations, was one of the most interesting events for me at ExL Pharma’s 6th Annual Public Relations & Communications Summit .
Read the full storyOn Being Voted Off the Social Media Island
Here’s a bit of irony.
Kopelow On CME: ‘We Trust There Won’t Be Fraud’
Continuing medical education is always controversial, given concerns over undue industry influence on medical practice. But CME roared back into public view earlier this month when several leading policy makers and physicians – including the National Institutes of Health director – publicly objected to a rule promulgated by the Accreditation Council for Continuing Medical Education, which would prevent doctors from receiving needed credit for attending medical meetings where industry people talk about their drugs
Read the full storyDeception and deceipt on social media
It’s easy for a pharma employee to set up a bogus social media account and violate FDA/DDMAC rules and guidelines. There are literally thousands of social media posts every minute of every day and frankly there is no way to really stop pharma and medical device employees from going on Twitter and making off-label or false claims
Read the full storyWhat an exciting time to be in DTC marketing
There are a lot of great quotes around change but the fact of the matter is that most people don’t embrace change because they are afraid of what change can mean. DTC marketing has been in a funk for a long time but consumers and patients are going to force DTC marketers to think out of the box and if drug marketing to consumers is to continue to be measured than new ways are going to have to be found to interact with patients
Live from BIO 2010: A human face for the drug industry
Yesterday I left Philadelphia for FierceBiotech’s annual trip to
Pharma Should Leave Unmoderated SM Discussions to 3rd Parties
In comments addressed to the FDA, many drug companies and ad hoc industry groups are suggesting ways drug companies can legally “engage” with patients, physicians, and consumers in online social media discussions (see, for example, ” A Pharma ‘Social Media Working Group’ Submits Comments to FDA “).
Disclosure: Does it blur the facts ?
I’m used to Ed Silverman’s constant attack on pharma via his Pharmalot BLOG. It seems he goes out of his way to point out everything that is wrong with pharma while never having worked a day in the industry. However journalists seem to get a “pass” when it comes to voicing their opinions
Lessons from Toyota disaster for the drug industry
According to a story from Newsweek titled Toyota’s Digital Disaster; How much more difficult does the Internet make crisis management? It’s a crucial front, and you have got to be there.
Read the full storyShould pharma develop Facebook pages ?
What happened to Twitter? The answer to that is the reason for its decline: nothing
Read the full story







Business Week – Drug Marketing
Business Week – Pharma Marketing
Cafe Pharma
Clinical Trials.gov
FDA on Twitter
Pharma Live
Pharma Voice